The price of Azenta Inc. (NASDAQ:AZTA) shares last traded on Wall Street fell -9.93% to $44.47.
Based on available information, 5 analysts follow Azenta Inc. (NASDAQ:AZTA). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $68.00 and a low of $45.00, we find $50.50. Given the previous closing price of $49.37, this indicates a potential upside of 2.29 percent. AZTA stock price is now 0.48% away from the 50-day moving average and -7.36% away from the 200-day moving average. The market capitalization of the company currently stands at $2.85B.
Among analysts, 3 rate the stock a hold while 2 rate it a buy. Brokers who have rated the stock have averaged $53.50 as their price target over the next twelve months.
In other news, MARTIN JOSEPH R, Director sold 2,400 shares of the company’s stock on Jun 06. The stock was sold for $103,368 at an average price of $43.07. Upon completion of the transaction, the Director now directly owns 85,175 shares in the company, valued at $3.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 19, EVP & Chief Operating Officer McManus Matthew bought 8,625 shares of the business’s stock. A total of $501,544 was incurred on buying the stock at an average price of $58.15. This leaves the insider owning 29,467 shares of the company worth $1.31 million. Insiders disposed of 55,727 shares of company stock worth roughly $2.48 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AZTA stock. A new stake in Azenta Inc. shares was purchased by ASSENAGON ASSET MANAGEMENT S.A. during the first quarter worth $35,084,000. LIGHTHOUSE INVESTMENT PARTNERS, LLC invested $14,542,000 in shares of AZTA during the first quarter. In the first quarter, VOLORIDGE INVESTMENT MANAGEMENT, LLC acquired a new stake in Azenta Inc. valued at approximately $12,119,000. PARK WEST ASSET MANAGEMENT LLC acquired a new stake in AZTA for approximately $11,118,000. NATIXIS purchased a new stake in AZTA valued at around $10,588,000 in the second quarter. In total, there are 479 active investors with 108.87% ownership of the company’s stock.
A candlestick chart of Azenta Inc. (NASDAQ: AZTA) showed a price of $47.50 on Thursday morning. During the past 12 months, Azenta Inc. has had a low of $36.01 and a high of $75.71. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.50, and a quick ratio of 6.70. The fifty day moving average price for AZTA is $44.27 and a two-hundred day moving average price translates $48.00 for the stock.
The latest earnings results from Azenta Inc. (NASDAQ: AZTA) was released for Mar, 2023. According to the Medical Instruments & Supplies Company, earnings per share came in at -$0.06, missing analysts’ expectations of -$0.02 by -0.04. This compares to $28.31 EPS in the same period last year. The net profit margin was -7.80% and return on equity was -1.50% for AZTA. The company reported revenue of $148.4 million for the quarter, compared to $145.54 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.96 percent. For the current quarter, analysts expect AZTA to generate $154.4M in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/23/2021. Investors who held shares on 12/03/2021 were paid a $0.10 dividend. On an annualized basis, this represents a $0.40 dividend and a 0.90% percent yield. There was an ex-dividend date of 12/02/2021 for this dividend.
Azenta Inc.(AZTA) Company Profile
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment’s services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
